Autolus Therapeutics/$AUTL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
- Ticker
- $AUTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 753
- Headquarters
- London, United Kingdom
- Website
- www.autolus.com
AUTL Metrics
BasicAdvanced
$476M
-
-$1.05
2.09
-
Price and volume
Market cap
$476M
Beta
2.09
52-week high
$2.58
52-week low
$1.18
Average daily volume
1.6M
Financial strength
Current ratio
4.886
Quick ratio
4.059
Long term debt to equity
4.665
Total debt to equity
4.915
Interest coverage (TTM)
-5.47%
Profitability
EBITDA (TTM)
-236.571
Gross margin (TTM)
-74.60%
Net profit margin (TTM)
-238.65%
Operating margin (TTM)
-210.49%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-25.44%
Return on equity (TTM)
-133.00%
Valuation
Price to revenue (TTM)
4.058
Price to book
6.37
Price to tangible book (TTM)
8.46
Price to free cash flow (TTM)
-1.978
Free cash flow yield (TTM)
-50.55%
Free cash flow per share (TTM)
-0.905
Growth
Revenue change (TTM)
292.16%
Earnings per share change (TTM)
20.46%
3-year revenue growth (CAGR)
150.30%
3-year earnings per share growth (CAGR)
-2.52%
What the Analysts think about AUTL
Analyst ratings (Buy, Hold, Sell) for Autolus Therapeutics stock.
Analyst projections of the future price of Autolus Therapeutics stock.
Bulls say / Bears say
AUCATZYL sales are scaling quickly: Q2 2026 revenue rose 119% year on year to $45.7 million, prompting Autolus to raise its full-year revenue guidance to $140–$150 million. Continued uptake could make the company less reliant on its pipeline. (Stock Titan)
Manufacturing economics are improving as volumes grow: gross margin reached 55% in Q2, up from 6% in Q1 and negative margins in 2025. That progress supports management’s aim to raise adult ALL margins further. (Stock Titan)
The FDA granted obe-cel RMAT designation for systemic lupus erythematosus and lupus nephritis, giving the company a regulatory development pathway for a potential use beyond cancer. This is a development advantage, not an approval, and the pivotal lupus nephritis study is still in progress. (GlobeNewswire)
The company remains loss-making and cash-hungry: it recorded a $39.1 million net loss in Q2 and used $90.4 million of cash in operations in the first half. Its stated runway depends in part on expected product sales and further credit-facility funding. (Stock Titan)
Autolus has $284.3 million of royalty and milestone financing liabilities, with imputed interest rates reaching 28.70%. Those obligations could absorb a material share of future product economics even as sales grow. (Stock Titan)
The pipeline offers no near-term commercial replacement for adult ALL: pivotal paediatric ALL data are expected at the end of 2027, while lupus nephritis data are expected in 2028. These opportunities remain dependent on clinical results and add years of development and funding risk. (Stockhouse)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.
AUTL Financial Performance
Revenues and expenses
AUTL Earnings Performance
Company profitability
Upcoming events
No upcoming events
AUTL News
AllArticlesVideos
Funds containing AUTL
AllUSDGBP
Fund name | Fund size | $AUTL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.